Headlines about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zynerba Pharmaceuticals earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.9901463392499 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news stories that may have impacted Accern’s rankings:

Zynerba Pharmaceuticals (ZYNE) traded down 4.45% on Friday, hitting $9.66. 728,788 shares of the stock traded hands. Zynerba Pharmaceuticals has a 12 month low of $5.80 and a 12 month high of $23.57. The firm has a 50-day moving average price of $7.35 and a 200-day moving average price of $7.35. The company’s market capitalization is $128.06 million.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last posted its earnings results on Tuesday, August 1st. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Analysts forecast that Zynerba Pharmaceuticals will post ($2.42) earnings per share for the current year.

Several research analysts have issued reports on the stock. Zacks Investment Research raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Roth Capital set a $30.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 10th. Oppenheimer Holdings, Inc. cut shares of Zynerba Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, August 14th. HC Wainwright cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $30.00 to $7.00 in a report on Tuesday, August 8th. Finally, Jefferies Group LLC cut shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their target price for the stock from $12.00 to $7.00 in a report on Tuesday, August 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Zynerba Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $14.63.

TRADEMARK VIOLATION WARNING: “Zynerba Pharmaceuticals (ZYNE) Given Daily Media Sentiment Rating of 0.23” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/zynerba-pharmaceuticals-zyne-given-daily-media-sentiment-rating-of-0-23/1615963.html.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Insider Buying and Selling by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.